HanxBio H1 FY26 loss narrows to RMB 33.24 million; other income and gains more than doubled to RMB 27.61 million

• HanxBio posted a net loss of RMB 33.24 million, essentially unchanged from the prior-year period.
• Other income and gains more than doubled to RMB 27.61 million, driven mainly by RMB 21.16 million fair-value gains on contingent consideration.
• R&D expenses fell 16.6% to RMB 26.1 million, while other expenses climbed to RMB 17.49 million on RMB 17.42 million FX losses.
• Cash and cash equivalents declined 18.6% to RMB 500.29 million.
• Pipeline progress included HX111 entering Phase 1 with 14 patients enrolled; HX009 advanced toward a planned pivotal Phase II in EBV+ DLBCL.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals (Wuhan) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260817-12286310), on August 17, 2026, and is solely responsible for the information contained therein.